Press Releases

 
Press Releases
  Date Title View
May 15, 2013
NEW HAVEN, Conn., May 15, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of David Apelian, M.D., Ph.D., MBA, to the position of Executive Vice President and Chief Medical Officer, effective May 28, 2013. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfoli...
PDF
May 9, 2013
NEW HAVEN, Conn., May 9, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that members of the senior management team will be presenting a company overview at three upcoming investor conferences: Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 at 3:00 p.m. PT at the Enco...
PDF
May 7, 2013
NEW HAVEN, Conn., May 7, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2013. For the first quarter of 2013, the Company reported a net loss of $11.7 million or $0.14 per share, compared with a net loss of $9.1 million or $0.13 per share for the first quar...
PDF
Apr 23, 2013
- Phase 1 Results Further Demonstrate Potency of ACH-3102 in Genotypes 1a and 1b and Against Resistant HCV-- Study Shows ACH-3102 and Sovaprevir Can be Co-Administered Without Interaction -- Total of Six Poster Presentations to be Made During EASL - AMSTERDAM, The Netherlands, April 23, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (...
PDF
Apr 23, 2013
- ACH-3102 deemed safe and well-tolerated following 12 weeks of therapy - - High barrier to resistance demonstrated with no on-treatment virologic breakthrough observed - - Novel NS5A inhibitor study supports differentiated profile of ACH-3102 - NEW HAVEN, Conn., April 23, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) ...
PDF
Apr 16, 2013
NEW HAVEN, Conn., April 16, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has initiated an international Phase 2 clinical trial with sovaprevir and ACH-3102 for the treatment of genotype 1 chronic hepatitis C (HCV). The trial will evaluate an all-oral 12-week interferon-free regimen consisting of sov...
PDF
Mar 1, 2013
NEW HAVEN, Conn., March 1, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that members of the senior management team will be presenting a company overview at two upcoming investor conferences: Cowen and Company 33rd Annual Health Care Conference on Monday, March 4, 2013 at 2:50 p.m. ET at The Boston Marr...
PDF
Feb 27, 2013
NEW HAVEN, Conn., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that the underwriters exercised their option to purchase an additional 1,894,410 shares from Achillion in its previously announced underwritten public offering of common stock at a price to the public of $8.40 per share. The offering of...
PDF
Feb 21, 2013
NEW HAVEN, Conn., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $8.40 per share. The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and c...
PDF
Feb 20, 2013
- Conference call and webcast to be held today, February 20th, at 5:00 pm EST - NEW HAVEN, Conn., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve months ended December 31, 2012. For the three months ended December 31, 2012, the Company reported a net l...
PDF
FirstPrevious
...
7
...
NextLast
Achillion Pharmaceuticals